Glycan modified nucleic acids, methods of preparation, and therapeutic uses

Patent metadata

Field	Value
Publication number	US-2024115714-A1
Application number	US-202318364753-A
Country	US
Kind code	A1
Filing date	Aug 3, 2023
Priority date	Apr 23, 2021
Publication date	Apr 11, 2024
Grant date	—

Abstract

The present disclosure relates to glyconucleic acids, such as glycoRNA and glycoDNA described herein. Provided are glycosylated ribonucleic acid (glycoRNA)-related methods and compositions.

First claim

1 - 29 . (canceled)

30 . A glyconucleic acid compound of Formula (I):
A-L-B  (I),
or a salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, or an isotopically enriched derivative thereof, wherein: A is a nucleic acid of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) comprising a first click-chemistry handle; B is an asparagine-linked glycan (N-glycan) comprising a second click-chemistry handle; and L comprises a linker formed by a biorthogonal click chemistry reaction between the first click-chemistry handle the second click-chemistry handle.

31 . The glyconucleic acid of claim 30 , wherein A is an RNA comprising a first click-chemistry handle.

32 . The glyconucleic acid of claim 30 , wherein A is an siRNA comprising a first click-chemistry handle.

33 . The glyconucleic acid of claim 30 , wherein A is an mRNA comprising a first click-chemistry handle.

34 . The glyconucleic acid of claim 30 , wherein A is a circular RNA comprising a first click-chemistry handle.

35 . (canceled)

36 . The glyconucleic acid of claim 30 , wherein A comprises a first click-chemistry handle selected from those listed in Table 4 under “Reagent A”, and wherein B comprises a second click-chemistry handle selected from those listed in Table 4 under “Reagent B”.

37 . The glyconucleic acid of claim 30 , wherein A comprises a first click-chemistry handle selected from those listed in Table 4 under “Reagent B”, and wherein B comprises a second click-chemistry handle selected from those listed in Table 4 under “Reagent A”.

38 . The glyconucleic acid of claim 30 , wherein B is an asparagine linked glycan comprising a bi-antennary glycan, wherein the bi-antennary glycan comprises a first terminal residue and a second terminal residue.

39 . The glyconucleic acid of claim 30 , wherein B is an asparagine linked glycan comprising a tri-antennary glycan, wherein the tri-antennary glycan comprises a first terminal residue, a second terminal residue and a third terminal residue.

40 . The glyconucleic acid of claim 38 , wherein at least one of the first terminal residue, the second terminal residue and the third terminal residue, if present, comprises sialic acid.

41 - 71 . (canceled)

Assignees

• Ganna Bio Inc
• Childrens Medical Ct Corp
• Beth Israel Deaconess Medical Ct Inc
• Univ Leland Stanford Junior

Inventors

• Flynn Ryan Alexander
• Goodman Brian
• Lawlor Ciaran
• Bisaria Namita
• Cummings Richard D
• Wei Mohui
• Bertozzi Carolyn R

Classifications

• A61K47/61 Primary

  the organic macromolecular compound being a polysaccharide or a derivative thereof · CPC title

• A61K47/549

  Sugars, nucleosides, nucleotides or nucleic acids · CPC title

• A61K31/713

  Double-stranded nucleic acids or oligonucleotides · CPC title

• A61K31/7088

  Compounds having three or more nucleosides or nucleotides · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title